Stealth BioTherapeutics Corp

Symbol: MITO




Market price today

  • -0.2758

    P/E Ratio

  • 0.0000

    PEG Ratio

  • 23.54M

    MRK Cap

  • 0.00%

    DIV Yield

Stealth BioTherapeutics Corp (MITO) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Ms. Irene P. McCarthy J.D.
Full-time employees:38
Address:190 Elgin Avenue, George Town

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.

General Outlook

In simple terms, Stealth BioTherapeutics Corp has 73.549 M shares that people are buying and selling right now.

Return on Investments

The company's asset efficiency, represented by a robust -1.071% return, is a testament to Stealth BioTherapeutics Corp's adeptness in optimizing resource deployment. Stealth BioTherapeutics Corp's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 1.932%. Furthermore, the proficiency of Stealth BioTherapeutics Corp in capital utilization is underscored by a remarkable -1.302% return on capital employed.

Stock Prices

Stealth BioTherapeutics Corp's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $0.3229, while its low point bottomed out at $0.3148. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Stealth BioTherapeutics Corp's stock market.

Liquidity Ratios

Analyzing MITO liquidity ratios reveals its financial health of the firm. The current ratio of 458.09% gauges short-term asset coverage for liabilities. The quick ratio (435.31%) assesses immediate liquidity, while the cash ratio (435.31%) indicates cash reserves.

Current Ratio458.09%
Quick Ratio435.31%
Cash Ratio435.31%

Profitability Ratios

The effective tax rate stands at -2.36%, revealing its tax efficiency. The net income per EBT, 102.36%, and the EBT per EBIT, 102.42%, provide insights into its earnings hierarchy.

Effective Tax Rate-2.36%
Net Income per EBT102.36%
EBT per EBIT102.42%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 4.58, it details the span from stock purchase to revenue. The 4 days it takes to settle debts showcases its creditor relations.

Days of Sales Outstanding435

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -0.97, and free cash flow per share, -0.97, depict cash generation on a per-share basis. The cash per share value, 1.02, showcases liquidity position.

Operating Cash Flow per Share-0.97
Free Cash Flow per Share-0.97
Cash per Share1.02
Free Cash Flow to Operating Cash Flow Ratio1.00
Cash Flow Coverage Ratio-3.29
Capital Expenditure Coverage Ratio-671.21
Dividend Paid and Capex Coverage Ratio-671.21

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 27.19%, highlights its total liabilities relative to assets. With a debt-equity ratio of -0.30, we discern the balance between debt and equity financing. The long-term debt to capitalization, -43.16%, and total debt to capitalization, -43.16%, ratios shed light on its capital structure. An interest coverage of -41.29 indicates its ability to manage interest expenses.

Debt Ratio27.19%
Debt Equity Ratio-0.30
Long Term Debt to Capitalization-43.16%
Total Debt to Capitalization-43.16%
Interest Coverage-41.29
Cash Flow to Debt Ratio-3.29
Company Equity Multiplier-1.11

Per Share Data

Net income per share, -1.13, reflects the portion of profit attributed to each share. The book value per share, -0.98, represents the net asset value distributed per share, while the tangible book value per share, -0.98, excludes intangible assets.

Net Income Per Share-1.13
Book Value Per Share-0.98
Tangible Book Value Per Share-0.98
Shareholders Equity Per Share-0.98
Interest Debt Per Share0.32

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 4,989,373.54, captures the company's total value, considering both debt and equity. Income quality, 0.86, assesses the reliability of reported earnings.

Enterprise Value4,989,373.54
Income Quality0.86
Capex to Operating Cash Flow0.15%
Capex to Depreciation-87.01%
Graham Number4.99
Return on Tangible Assets-104.58%
Graham Net Net-1.04
Working Capital38,774,000
Tangible Asset Value-45,295,000
Net Current Asset Value-45,919,000
Average Payables3,496,500

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, -0.33, and the price to book ratio, -0.33, reflect the market's valuation relative to the company's book value.

Price Book Value Ratio-0.33
Price to Book Ratio-0.33
Price Cash Flow Ratio-0.33
Enterprise Value Multiple-0.65
Price Fair Value-0.33
Price to Operating Cash Flow Ratio-0.33
Price to Tangible Book Ratio-0.85
Enterprise Value Over EBITDA-0.10
EV to Operating Cash Flow-0.11
Earnings Yield-136.55%
Free Cash Flow Yield-117.08%
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Stealth BioTherapeutics Corp (MITO) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -0.276 in 2024.

What is the ticker symbol of Stealth BioTherapeutics Corp stock?

The ticker symbol of Stealth BioTherapeutics Corp stock is MITO.

What is company IPO date?

IPO date of Stealth BioTherapeutics Corp is 2019-02-15.

What is company current share price?

Current share price is 0.320 USD.

What is stock market cap today?

The market cap of stock today is 23535552.000.

What is PEG ratio in 2024?

The current 0.000 is 0.000 in 2024.

What is the number of employees in 2024?

In 2024 the company has 38.